Using AI to predict lymph node metastasis in cervical cancer patients
Development of an Imaging Prediction Model for Pelvic Lymph Node Metastasis of Cervical Cancer Using Artificial Intelligence Techniques.
This study is testing if artificial intelligence can help predict whether cervical cancer has spread to lymph nodes before surgery, to improve treatment decisions for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 4000 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | Female |
| Sponsor | Obstetrics & Gynecology Hospital of Fudan University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06448897 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop and validate a preoperative model for predicting lymphatic metastasis in cervical cancer patients using artificial intelligence techniques. By analyzing preoperative imaging and correlating it with postoperative pathological findings, the study seeks to enhance the accuracy of lymphatic metastasis predictions. The model will be trained on data collected from patients who underwent surgery for invasive cervical cancer at a single center. This approach could provide valuable insights for treatment decisions in managing cervical cancer.
Who should consider this trial
Good fit: Ideal candidates include patients aged 18 to 80 with a preoperative diagnosis of invasive cervical cancer stages I-III who have undergone specific surgical procedures.
Not a fit: Patients who are pregnant, have received prior chemotherapy or radiotherapy, or have other malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this model could significantly improve preoperative decision-making and treatment planning for cervical cancer patients.
How similar studies have performed: While the use of AI in medical imaging is a growing field, this specific approach to predicting lymph node metastasis in cervical cancer is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: 1. patients with preoperative diagnosis of invasive cervical cancer stage I-III, with any type of pathology, and patients who underwent radical/modified radical cervical cancer surgery + pelvic lymph node dissection in our hospital. 2. Age ≥18 years old and ≤80 years old 3. patients with complete preoperative pelvic MRI images and postoperative pathology and clinical data in our hospital Exclusion criteria: 1. Patients during pregnancy or breastfeeding, patients within 42 days of abortion 2. Patients who have received neoadjuvant chemotherapy or radiotherapy before surgery for this previous cervical cancer 3. Patients with other malignant tumors within 5 years 4. Combination of other underlying diseases that may lead to enlarged pelvic lymph nodes 5. Imaging report more than 1 month prior to surgery 6. Poor image quality and unrecognizable
Where this trial is running
Shanghai, Shanghai Municipality
- The Obstetrics and Gynecology Hospital of Fudan University — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Study coordinator: Xin Wu
- Email: wuxin_fc@fudan.edu.cn
- Phone: (021)33189900
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.